<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01195363</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20070253H</org_study_id>
    <nct_id>NCT01195363</nct_id>
  </id_info>
  <brief_title>Quetiapine Sr as Adjunctive Treatment In Mixed States of Bipolar Disorder</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo Controlled Study Of Quetiapine SR (QTP) As Adjunctive Treatment In Mixed States (MS) Of Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the acute and long-term bimodal efficacy of QTP, as an adjunct to ongoing treatment
      with lithium (Li) or divalproex (DIV) or lamotrigine (LAM) or any combination of the three
      thereof, in a group of patients with an index episode of a mixed state in BD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Whose Mood Improved According to MADRS and YMRS Scale Scores.</measure>
    <time_frame>Baseline visit to week 24</time_frame>
    <description>The primary outcome measure was assessed by 50% reduction in: 1. depression scores on the Montgomery Asberg Depression Rating Scale (MADRS), which ranges from 0 indicating no symptoms to 60 indicating most symptoms 2. mania scores on the Young Mania Rating Scale (YMRS), which ranges from 0 indicating no symptoms to 60 indicating most symptoms.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>quetiapine SR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>quetiapine SR, 200-600mg, po, qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>quetiapine sr Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>quetiapine SR placebo, 200-600mg, po qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>quetiapine SR</intervention_name>
    <description>quetiapine SR, dose range 200-600mg, each night QHS for 6mos</description>
    <arm_group_label>quetiapine SR</arm_group_label>
    <other_name>Seroquel SR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>quetiapine sr placebo</intervention_name>
    <description>quetiapine sr placebo, dose range 200-600mg, each night QHS for 6mos</description>
    <arm_group_label>quetiapine sr Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female;

          -  Age 18 years and older

          -  Patients on:

               -  Li at a stable dose for 4 weeks or longer, and a serum level at screening of 0.5
                  mEq/l OR

               -  DIV dose for 4 weeks or longer, and a serum level at screening of 45 g/ml OR

               -  LAM (dosage/day â‰¥100mg) at a stable dose for 4 weeks or longer OR

               -  Any combination 3a, 3b, or 3c

          -  Patients meeting DSM-IV TR diagnosis of bipolar disorder, I or II, as assessed using
             the MINI, (Sheehan et al., 1998) PLUS any ONE of criteria 5 or 6 or 7

          -  Patients meeting DSM-IV TR diagnostic criteria for a mixed manic episode with Young
             Mania Rating Scale (YMRS) score&gt;/=14 and Montgomery Asberg Depression Rating Scale
             (MADRS) score&gt;/=14

          -  Patients meeting the criteria for a manic/hypomanic episode for at least 2 days with
             the simultaneous presence of Young Mania Rating Scale (YMRS) score&gt;/=14 PLUS
             Montgomery Asberg Depression Rating Scale (MADRS) score&gt;/=14 ;

          -  Patients meeting DSM-IV TR diagnostic criteria for a major depressive episode with the
             simultaneous presence of MADRS score&gt;/=14 PLUS meeting the criteria for a
             manic/hypomanic episode for at least 2 days with the simultaneous presence of Young
             Mania Rating Scale (YMRS) score&gt;/=14

        Exclusion Criteria:

          -  Patients with a current Axis I diagnosis of schizophrenia, schizophreniform disorder,
             schizotypal disorder, bipolar disorder with psychotic subtype, drug induced mania or
             AIDS induced mania

          -  Women with a positive pregnancy test or who are lactating

          -  Women of child-bearing potential who are not practicing a clinically accepted method
             of contraception

          -  Patients with general medical conditions that contraindicate psychoactive medications
             or uncontrolled medical disorder or central nervous system diseases.

          -  Patients whose clinical status requires inpatient or day hospital treatment

          -  History of severe side effects associated with therapeutic doses of Li, DIV, LAM

          -  Alcohol or drug dependent at time of enrollment

          -  Suicidal at time of enrollment.

          -  Current or previous exposure to QTP
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Bowden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2010</study_first_submitted>
  <study_first_submitted_qc>September 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2010</study_first_posted>
  <results_first_submitted>April 3, 2013</results_first_submitted>
  <results_first_submitted_qc>February 10, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 12, 2015</results_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Charles L. Bowden</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>bipolar disorder, mania, depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited in our University, Center for Healthcare Services, and by televison ads between Oct 2007 and January 2011.</recruitment_details>
      <pre_assignment_details>Patients screened over a 7 day period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Quetiapine SR, 200-600mg , po, QD</title>
          <description>mood stabilizer plus active quetiapine SR</description>
        </group>
        <group group_id="P2">
          <title>Quetiapine sr Placebo 200-600mg, po, qd</title>
          <description>mood stabilizer plus quetiapine SR placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>incarceration</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Quetiapine SR</title>
          <description>mood stabilizer plus active quetiapine sr</description>
        </group>
        <group group_id="B2">
          <title>Quetiapine SR Placebo</title>
          <description>mood stabilizer plus quetiapine SR placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.5" spread="10.1"/>
                    <measurement group_id="B2" value="32.1" spread="9.8"/>
                    <measurement group_id="B3" value="34" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Whose Mood Improved According to MADRS and YMRS Scale Scores.</title>
        <description>The primary outcome measure was assessed by 50% reduction in: 1. depression scores on the Montgomery Asberg Depression Rating Scale (MADRS), which ranges from 0 indicating no symptoms to 60 indicating most symptoms 2. mania scores on the Young Mania Rating Scale (YMRS), which ranges from 0 indicating no symptoms to 60 indicating most symptoms.</description>
        <time_frame>Baseline visit to week 24</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Active Quetiapine S.R., 200-600mg, po, qd</title>
            <description>Atypical antipsychotic quetiapine S.R. plus mood stabilizer</description>
          </group>
          <group group_id="O2">
            <title>Placebo Quetiapine S.R. 200-600mg, po, qd</title>
            <description>mood stabilizer plus quetiapine S.R. placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Whose Mood Improved According to MADRS and YMRS Scale Scores.</title>
          <description>The primary outcome measure was assessed by 50% reduction in: 1. depression scores on the Montgomery Asberg Depression Rating Scale (MADRS), which ranges from 0 indicating no symptoms to 60 indicating most symptoms 2. mania scores on the Young Mania Rating Scale (YMRS), which ranges from 0 indicating no symptoms to 60 indicating most symptoms.</description>
          <population>Per Protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MADRS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>YMRS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10/30/2007 - 6/1/2011, 2 yrs 8 mos.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mood Stabilizer Plus Quetiapine SR</title>
          <description>mood stabilizer plus active quetiapine SR</description>
        </group>
        <group group_id="E2">
          <title>Mood Stabilizer Plus Quetiapine sr Placebo</title>
          <description>mood stabilizer plus quetiapine SR placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>joint pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>drowsiness/sedation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>interrupted sleep</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>increased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Overall limitations were screen failures and lost to follow-ups which led to not reaching recruitment goals.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Charles L Bowden, MD</name_or_title>
      <organization>UTHSCSA</organization>
      <phone>210-567-5393</phone>
      <email>BowdenC@uthscsa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

